Okay, this is for the serious readers only. The Journal of Clinical Oncology has updated the clinical practice guidelines for chemo and radiation protectants for patients with cancer. Just a warning it reads like this Dexrazoxane is not recommended for routine use in breast cancer (BC) in adjuvant setting, or metastatic setting with initial doxorubicin-based chemotherapy. Consider use with metastatic BC and other malignancies, for patients who have received more than 300 mg/m 2 doxorubicin who may benefit from continued doxorubicin-containing therapy. Cardiac monitoring should continue in patients receiving doxorubicin.